Table 2

- Summary of isotretinoin-related key adverse events.

Variable	Total study population (N=230)	P-value^{^*}	Male group (n=33) n (%)	Female group (n=197) n (%)	P-value^{^§}
Reported ≥1 adverse effects of isotretinoin therapy
Yes	189 (82.2%)	<0.0001^{^*}	23 (69.7%)	166 (84.3%)	0.0289§
No	41 (17.8%)	<0.0001^{^*}	10 (30.3%)	31 (15.7%)	0.0289§
Increase skin sensitivity to sunlight
Yes	127 (55.2%)	0.1550	17 (51.5%)	110 (55.8%)	0.7069
No	103 (44.8%)	0.1550	16 (48.5%)	87 (44.2%)	0.7069
Xerophthalmia
Yes	177 (77%)	<0.0001^{^*}	21 (63.6%)	156 (79.2%)	0.0716
No	53 (23%)	<0.0001^{^*}	12 (36.4%)	41 (20.8%)	0.0716
Average dose causing Xerophthalmia (mg)	29.1 ± 10	-	32 ± 8.3	30.77 ± 9.36	0.5781
Dry lips
Yes	213 (92.6%)	<0.0001^{^*}	31 (93.9%)	182 (92.4%)	0.7522
No	17 (7.4%)	<0.0001^{^*}	2 (6.1%)	15 (7.6%)	0.7522
Average dose causing dry lips (mg)	30.9 ± 9.2	-	28.33 ± 9.1	29.18 ± 10.2	0.6683
Obstructed nose
Yes	77 (33.1%)	<0.0001^{^*}	10 (30.3%)	66 (33.5%)	0.8715
No	154 (66.9%)	<0.0001^{^*}	23 (69.7%)	131 (66.5%)	0.8715
Average dose causing obstructed nose (mg)	32.02 ± 9.4	-	28.88 ± 9.3	32.6 ± 9.3	0.2696
Dry nose
Yes	155 (67.4%)	<0.0001^{^*}	20 (60.6%)	135 (68.5%)
No	75 (32.6%)	<0.0001^{^*}	13 (39.4%)	62 (31.5%)	0.4853
Average dose causing dry nose (mg)	32.13 ± 9.3	-	29.5 ± 7.6	31.9 ± 9.3	0.2836

↵* Statistically significant difference between variables in the total study population (p<0.05).
↵§ Statistically significant difference between male and female groups (p<0.05).